Provider
Weight loss service, IV therapy service, Medical clinic, Medical spa, Men's health physician, Women's health clinic, Wellness center
Indexable treatment evidence

Highland Longevity has source-ready treatment evidence for Semaglutide evidence, Tirzepatide evidence. Confirm current medication availability, pharmacy model, and pricing before booking.

Highland Longevity

4.9(52 reviews)Google
Fort Worth, Texas
Semaglutide evidence, Tirzepatide evidence
Compare with other providers
+1 214-444-9796

Type

Provider

Location

Fort Worth, Texas

Starting At

Rating

4.9/5 (52 reviews)

About This Provider

Highland Longevity is a provider listed in the GLP1Search directory serving patients in Fort Worth, Texas. Public listing data includes source-ready evidence for Semaglutide evidence, Tirzepatide evidence; confirm current treatment availability directly with the provider.

Visit their website at highlandlongevity.com for the most current information on pricing, medications, and availability.

Google Reviews

4.9

Based on 52 Google reviews

Google

Rating Distribution (estimated)

52 total reviews

5
70%
4
20%
3
5%
2
3%
1
2%

Business Details

What Patients Should Know

Before You Start

Confirm total monthly costs upfront — including membership fees, medication costs, and consultation charges. Ask about insurance coverage.

Medication Options

GLP-1 medications include Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound). Ask which options are available and their sourcing.

Clinical Oversight

Verify your assigned clinician's credentials. Ensure regular check-ins and dose adjustments are part of the program.

Our Independence

GLP1Search does not accept referral fees. All provider data is collected independently from public sources.

Get weekly GLP-1 pricing updates

Provider comparisons, new clinic alerts, and research — delivered to your inbox.

No spam. Unsubscribe anytime.

Not sure which provider is right for you?

Every body is different. Compare pricing, medication options, pharmacy standards, and patient experiences across all 18,771 public provider records, with treatment-evidence and directory-only labels kept separate.